 I. To eliminate exposure to conventional chemotherapy including anthracyclines, for patients with standard risk acute promyelocytic leukemia APL, through use of arsenic trioxide ATO and all-trans retinoic acid ATRA tretinoin based therapy while achieving an event free survival EFS that is not inferior compared to historical controls. 